Scott predicts ongoing off-and-on shortages

The Hill called compounding GLP1s a “loophole,” but otherwise wrote a decent piece explaining how telehealth companies are able to sell compounded semaglutide and tirzepatide. And it quoted Scott explaining that brand-name versions probably won’t stick around. “We’ll see them right back on the drug shortage list because of the extraordinary demand.”